Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 28 for:    stem cell Spinal Cord Injury AND marrow

Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study (SciExVR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03225625
Recruitment Status : Recruiting
First Posted : July 21, 2017
Last Update Posted : June 3, 2019
Sponsor:
Collaborator:
The Healing Institute
Information provided by (Responsible Party):
MD Stem Cells

Brief Summary:
The SciExVR study will evaluate the potential benefit of autologous bone marrow derived stem cells (BMSC) in the treatment of spinal cord injury with evidence of impaired motor or sensory function. The treatment consists of bilateral paraspinal injections of the BMSC at the level of the injury as well as superior and inferior to that spinal segment followed by an intravenous injection and intranasal placement. Patients undergoing BMSC treatment may also be assigned to use of exoskeletal movement (or equivalent) or virtual reality visualization (or equivalent) to augment upper motor neuron firing and/or receptivity of the sensory neurons. http://mdstemcells.com/sciexvr/

Condition or disease Intervention/treatment Phase
Spinal Cord Injuries Spinal Cord Compression Spinal Cord Ischemia Spinal Cord Diseases Spinal Paralysis Paraplegia Paraplegia, Spinal Paraplegia/Paraparesis Paraplegia; Traumatic SCI - Spinal Cord Injury Procedure: Paraspinal Procedure: Paraspinal EX Procedure: Paraspinal VR Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

There will be 3 Arms:

Arm 1: BMSC Paraspinal, IV, Intranasal . Arm 2: BMSC Paraspinal,IV,Intranasal + exoskeleton or equivalent . Arm 3: BMSC Paraspinal, IV, Intranasal + virtual reality or equivalent .

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study
Actual Study Start Date : July 1, 2017
Estimated Primary Completion Date : July 1, 2021
Estimated Study Completion Date : July 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Paraspinal
Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
Procedure: Paraspinal
BMSC provided by paraspinal injection, intravenous and intranasal
Other Name: Arm 1

Experimental: Paraspinal EX

Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.

Exoskeleton or equivalent stimulation following this treatment.

Procedure: Paraspinal
BMSC provided by paraspinal injection, intravenous and intranasal
Other Name: Arm 1

Procedure: Paraspinal EX
BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
Other Name: Arm 2

Experimental: Paraspinal VR

Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.

Virtual Reality or equivalent visualization following this treatment.

Procedure: Paraspinal
BMSC provided by paraspinal injection, intravenous and intranasal
Other Name: Arm 1

Procedure: Paraspinal VR
BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
Other Name: Arm 3




Primary Outcome Measures :
  1. American Spinal Injury Association (ASIA) Impairment Scale (AIS) [ Time Frame: Pre-procedure, 1,3,6 and 12 months post-procedure ]
    AIS is based on the Frankel scale which is used to classify the degree or completeness of spinal cord injury (SCI) by assessing motor and sensory function. Patients will have AIS assessment prior to procedure and post-procedure for comparison and identification of any improvements in motor or sensory function.


Secondary Outcome Measures :
  1. Autonomic Nervous System (ANS) Function [ Time Frame: 1,3,6 and 12 months post-procedure ]
    The autonomic nervous system (ANS) through the sympathetic and parasympathetic divisions is responsible for many functions of the body including bladder and bowel control and sweating. Patients will self-report changes in ANS function and their abilities to perform ANS functions following the procedure.

  2. General Well-Being [ Time Frame: 1,3,6,12 months post-procedure ]
    General Well-Being is a term that may encompass mood, sense of well-being, family relationships, ability to do daily tasks and other practical or emotional practices that vary from person to person. Patients will self-report changes in their Quality of Life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have documented functional damage to the spinal cord unlikely to improve with present standard of care.
  • If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated spinal cord damage as a result of the ongoing pharmacologic or surgical treatment.
  • In the estimation of Dr. Weiss and Dr. Silberfarb have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
  • Be over the age of 18 and capable of providing informed consent.
  • Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.

Exclusion Criteria:

  • All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.
  • Patients must be capable and willing to undergo follow up neurologic exams as outlined in the protocol.
  • Patients must be capable of providing informed consent.
  • In the estimation of Dr. Weiss and Dr. Silberfarb the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .
  • Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.
  • Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03225625


Contacts
Layout table for location contacts
Contact: Steven Levy, MD 203-423-9494 stevenlevy@mdstemcells.com

Locations
Layout table for location information
United States, Florida
The Healing Institute Recruiting
Margate, Florida, United States, 33063
Contact: Steven Levy, MD    203-423-9494    stevenlevy@mdstemcells.com   
Sponsors and Collaborators
MD Stem Cells
The Healing Institute
Investigators
Layout table for investigator information
Study Director: Steven Levy, MD MD Stem Cells
Principal Investigator: Jeffrey Weiss, MD The Healing Institute
Principal Investigator: Steven Silberfarb, DO Florida Orthopaedics and Spine Center

Additional Information:
Layout table for additonal information
Responsible Party: MD Stem Cells
ClinicalTrials.gov Identifier: NCT03225625     History of Changes
Other Study ID Numbers: SciExVR
First Posted: July 21, 2017    Key Record Dates
Last Update Posted: June 3, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by MD Stem Cells:
spinal cord injury
spinal cord compression
spinal cord ischemia
spinal cord diseases
spinal paralysis
paraplegia
paraparesis
SCI

Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Spinal Cord Injuries
Spinal Cord Compression
Spinal Cord Diseases
Spinal Cord Ischemia
Pathologic Processes
Trauma, Nervous System
Spinal Cord Vascular Diseases
Ischemia
Paralysis
Paraplegia
Paraparesis
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Paresis
Vascular Diseases
Cardiovascular Diseases